TY - JOUR
T1 - Development of a diagnostic screening strategy for niemann-pick diseases based on simultaneous liquid chromatography-tandem mass spectrometry analyses of n-palmitoyl-o-phosphocholine-serine and sphingosylphosphorylcholine
AU - Iwahori, Anna
AU - Maekawa, Masamitsu
AU - Narita, Aya
AU - Kato, Akie
AU - Sato, Toshihiro
AU - Ogura, Jiro
AU - Sato, Yu
AU - Kikuchi, Masafumi
AU - Noguchi, Atsuko
AU - Higaki, Katsumi
AU - Okuyama, Torayuki
AU - Takahashi, Tsutomu
AU - Eto, Yoshikatsu
AU - Mano, Nariyasu
N1 - Funding Information:
Acknowledgments We are grateful to all the donors who provided us their valuable serum samples and to doctors who collected the serum samples. This work was supported in part by JSPS KAKENHI 18K15699.
Publisher Copyright:
© 2020 The Pharmaceutical Society of Japan
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Early diagnosis of Niemann-Pick diseases (NPDs) is important for better prognosis of such diseases. N-Palmitoyl-O-phosphocholine-serine (PPCS) is a new NPD biomarker possessing high sensitivity, and with its combination with sphingosylphosphocholine (SPC) it may be possible to distinguish NPD-C from NPD-A/B. In this study, a rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (method 1) and a validated LC-MS/MS analysis (method 2) of PPCS and SPC were developed, and we have proposed a diagnostic screening strategy for NPDs using a combination of serum PPCS and SPC concentrations. Nexera and API 5000 were used as LC-MS/MS systems. C18 columns with lengths of 10 and 50mm were used for method 1 and 2, respectively. 2H3-Labeled PPCS and nor-SPC were used as internal standards. Selective reaction monitoring in positive-ion mode was used for MS/MS. Run times of 1.2 and 8min were set for methods 1 and 2, respectively. In both methods 1 and 2, two analytes showed high linearity in the range of 1-4000ng/mL. Method 2 provided high accuracy and precision in method validation. Serum concentrations of both analytes were significantly higher in NPD-C patients than those of healthy subjects in both methods. Serum PPCS correlated between methods 1 and 2; however, it was different in the case of SPC. The serum PPCS/SPC ratio was different in healthy subjects, NPD-C, and NPD-A/B. These results suggest that using a combination of the two LC-MS/MS analytical methods for PPCS and SPC is useful for diagnostic screening of NPDs.
AB - Early diagnosis of Niemann-Pick diseases (NPDs) is important for better prognosis of such diseases. N-Palmitoyl-O-phosphocholine-serine (PPCS) is a new NPD biomarker possessing high sensitivity, and with its combination with sphingosylphosphocholine (SPC) it may be possible to distinguish NPD-C from NPD-A/B. In this study, a rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (method 1) and a validated LC-MS/MS analysis (method 2) of PPCS and SPC were developed, and we have proposed a diagnostic screening strategy for NPDs using a combination of serum PPCS and SPC concentrations. Nexera and API 5000 were used as LC-MS/MS systems. C18 columns with lengths of 10 and 50mm were used for method 1 and 2, respectively. 2H3-Labeled PPCS and nor-SPC were used as internal standards. Selective reaction monitoring in positive-ion mode was used for MS/MS. Run times of 1.2 and 8min were set for methods 1 and 2, respectively. In both methods 1 and 2, two analytes showed high linearity in the range of 1-4000ng/mL. Method 2 provided high accuracy and precision in method validation. Serum concentrations of both analytes were significantly higher in NPD-C patients than those of healthy subjects in both methods. Serum PPCS correlated between methods 1 and 2; however, it was different in the case of SPC. The serum PPCS/SPC ratio was different in healthy subjects, NPD-C, and NPD-A/B. These results suggest that using a combination of the two LC-MS/MS analytical methods for PPCS and SPC is useful for diagnostic screening of NPDs.
KW - Discrimination
KW - Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
KW - N-palmitoyl-O-phosphocholine-serine
KW - Niemann-Pick disease
KW - Screening
KW - Sphingosylphosphocholine
UR - http://www.scopus.com/inward/record.url?scp=85090280024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090280024&partnerID=8YFLogxK
U2 - 10.1248/bpb.b20-00400
DO - 10.1248/bpb.b20-00400
M3 - Article
C2 - 32581190
AN - SCOPUS:85090280024
SN - 0918-6158
VL - 43
SP - 1398
EP - 1406
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 9
ER -